Sun Pharmaceutical Industries Limited has announced a significant expansion of its oncology portfolio through the acquisition of Checkpoint Therapeutics, Inc., a U.S.-based immunotherapy and targeted oncology company. The deal, valued at approximately $355 million, is expected to close in the second quarter of 2025, subject to regulatory and shareholder approvals. This strategic move will add Checkpoint’s FDA-approved skin cancer treatment, UNLOXCYT (cosibelimab-ipdl), to Sun Pharma’s global onco-derm franchise.
UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC), a form of skin cancer. By leveraging Sun Pharma’s global presence, the company aims to accelerate patient access to this critical treatment option. The acquisition represents a significant premium of approximately 66% to Checkpoint’s closing share price on March 7, 2025, reflecting Sun Pharma’s commitment to strengthening its position in the oncology market.
Checkpoint shareholders will receive an upfront cash payment of $4.10 per share, with the potential for an additional $0.70 per share if cosibelimab secures regulatory approval in select European markets within specified deadlines. This contingent value right (CVR) provides an incentive for further growth and expansion of UNLOXCYT’s market reach.
Strategic Implications and Market Potential:
The acquisition of Checkpoint Therapeutics marks a strategic expansion of Sun Pharma’s oncology offerings, particularly in the onco-dermatology segment. By integrating UNLOXCYT into its portfolio, Sun Pharma aims to enhance its global presence in treating skin cancers. The U.S. market opportunity for UNLOXCYT is estimated to be between $1 billion and $1.6 billion annually, with potential for significant revenue growth if the drug captures a substantial market share.
Analysts view this acquisition as a positive step for Sun Pharma, as it bolsters the company’s innovative portfolio in onco-derm therapy. Dilip Shanghvi, Chairman and Managing Director of Sun Pharma, highlighted the potential benefits of combining UNLOXCYT with Sun Pharma’s global reach, stating that it will provide patients with access to an important new treatment option.
The deal also includes a royalty agreement with Fortress Biotech, Checkpoint’s controlling shareholder, which will receive payments based on future sales of cosibelimab. This arrangement underscores the collaborative nature of the acquisition and ensures that all stakeholders benefit from the transaction.
Impact on Sun Pharma and Checkpoint Therapeutics:
The deal is likely to benefit both Sun Pharma and Checkpoint Therapeutics. Sun Pharma sees it as a substantial development of its oncology expertise, increasing its global position in the treatment of skin cancers. The addition of UNLOXCYT to Sun Pharma’s portfolio will allow the company to provide a greater range of therapies to patients around the world.
Checkpoint Therapeutics, on the other hand, will benefit from Sun Pharma’s extensive distribution network and marketing capabilities. James Oliviero, President and CEO of Checkpoint, expressed pride in the company’s achievement of securing FDA approval for UNLOXCYT and enthusiasm for the partnership with Sun Pharma, which he believes will maximize value for Checkpoint’s stockholders and accelerate access to UNLOXCYT globally.
Future Prospects and Market Dynamics:
As Sun Pharma completes the acquisition of Checkpoint Therapeutics, the company is poised to strengthen its position in the global oncology market. The integration of UNLOXCYT into Sun Pharma’s portfolio will not only expand its offerings but also enhance its competitive edge in the onco-dermatology segment.
The future success of this acquisition will depend on Sun Pharma’s ability to leverage its global presence effectively and navigate the regulatory landscape in various markets. The company’s commitment to improving access to critical treatments like UNLOXCYT aligns with its broader strategy to enhance patient care and drive innovation in the pharmaceutical sector.
In conclusion, Sun Pharma’s acquisition of Checkpoint Therapeutics represents a strategic move to bolster its oncology portfolio and expand its global reach in treating skin cancers. As the transaction progresses, it will be crucial for Sun Pharma to effectively integrate UNLOXCYT into its operations and capitalize on the market potential of this FDA-approved treatment.
